bortezomib (Velcade)
Jump to navigation
Jump to search
Introduction
Tradename: Velcade (FDA approved 2003)
Indications
- multiple myeloma
- refractory multiple myeloma (28% of patients improve for 1 year)[1][2]
- in combination with dexamethasone +/- thalidomide for induction prior to high-dose chemotherapy with hematopoietic stem cell transplantation [NGC,NICE]
- treatment of amyloidosis in combination with cycloposphamide & dexamethasone[3]
- mantle cell lymphoma[5]
Dosage
injectable agent
Adverse effects
- neutrophilic dermatosis
- reactivation of Herpes zoster
- prophylactic acyclovir or valacyclovir indicated regardless of Herpes zoster immunization status[6]
- peripheral neuropathy[6]
Mechanism of action
- inhibits proteasomes involved in cell proliferation
More general terms
References
- ↑ 1.0 1.1 Prescriber's Letter 10(6):35 2003
- ↑ 2.0 2.1 Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16;352(24):2487-98. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15958804
- ↑ 3.0 3.1 Mikhael JR et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012 May 10; 119:4391. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22331188
Venner CP et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012 May 10; 119:4387. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22331187 - ↑ San Miguel JF, Schlag R, Khuageva NK et al Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28;359(9):906-17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/1875364
- ↑ 5.0 5.1 Deprecated Reference
- ↑ 6.0 6.1 6.2 6.3 Medical Knowledge Self Assessment Program (MKSAP) 17, 18, 19 American College of Physicians, Philadelphia 2015, 2018, 2022
Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022